Publications
- Prospective observational study in comorbid patients with chronic lymphocytic leukemia receiving first-line bendamustine with rituximab2019 | Faculty of Medicine in Hradec Králové, Third Faculty of Medicine, First Faculty of Medicine
- Single-agent ibrutinib in RESONATE-2TM and RESONATETM versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia2019 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine
- Experiences in the treatment of refractory chylothorax associated with lymphoproliferative disorders2019 | Faculty of Medicine in Hradec Králové
- Alternating R-CHOP and R-cytarabine is a safe and effective regimen for transplant-ineligible patients with a newly diagnosed mantle cell lymphoma2018 | Faculty of Medicine in Hradec Králové, Third Faculty of Medicine, First Faculty of Medicine, Second Faculty of Medicine
- Five years of experience with rituximab plus high-dose dexamethasone for relapsed/refractory chronic lymphocytic leukemia2016 | Faculty of Medicine in Hradec Králové
- Treatment of patients with recurrent/refractory aggressive non-Hodgkin's lymphoma: effectiveness and safety of pixantrone2016 | Faculty of Medicine in Hradec Králové
- Rituximab infusion-related toxicity in patients with chronic lymphocytic leukemia2015 | Faculty of Medicine in Hradec Králové
- Ofatumumab2011 | Faculty of Medicine in Hradec Králové
- Thrombophilic conditions - laboratory and clinical diagnostics +12007 | Faculty of Medicine in Hradec Králové
- Idelalisib plus rituximab versus ibrutinib in the treatment of relapsed/refractory chronic lymphocytic leukaemia: A real-world analysis from the Chronic Lymphocytic Leukemia Patients Registry (CLLEAR)2023 | Faculty of Medicine in Hradec Králové, Third Faculty of Medicine, First Faculty of Medicine
Loading network view...
